(ARCT) Arcturus Therapeutics Holdings Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ARCT) Arcturus Therapeutics Holdings Inc. Complete Analysis Pack
Arcturus Therapeutics: Business Model Canvas in Focus
Unlock the full strategic blueprint behind Arcturus Therapeutics Holdings Inc.’s business model. This concise Business Model Canvas highlights how the company creates value, partners for growth, and navigates the competitive biotech landscape. Ideal for investors, analysts, and strategists seeking clear, actionable insight.
Partnerships
Vinbiocare COVID-19 vaccine manufacturing
Arcturus partnered with Vinbiocare Biotechnology Joint Stock Company to move COVID-19 vaccine work from development into local manufacturing and scale-up in Vietnam. The link mattered commercially too: Arcturus’ ARCT-154 showed 55.2% efficacy against symptomatic Omicron infection in Vietnam phase 3 data, supporting regional production demand.
Janssen hepatitis B nucleic-acid therapy
Arcturus Therapeutics Holdings Inc. and Janssen Pharmaceuticals, Inc. collaborate on nucleic acid-based hepatitis B therapies, pairing Arcturus RNA delivery tech with Janssen’s late-stage development expertise. The deal broadens Arcturus Therapeutics Holdings Inc.’s infectious-disease pipeline and supports work on chronic HBV, which still affects about 254 million people worldwide.
Ultragenyx rare-disease mRNA programs
Arcturus Therapeutics Holdings Inc. works with Ultragenyx Pharmaceutical, Inc. on mRNA therapies for rare-disease targets, extending the platform beyond Arcturus-owned programs. This alliance fits Arcturus’s rare-disease focus, where even one approved therapy can address a small patient base and still create meaningful value.
CureVac mRNA therapeutic and vaccine candidates
Arcturus Therapeutics Holdings Inc. works with CureVac AG on mRNA therapeutic and vaccine candidates across multiple indications, widening the pipeline beyond a single disease area and backing platform validation. In Arcturus Therapeutics Holdings Inc. latest reported year, this kind of multi-program partnering fits a company that booked $174.6 million in revenue in 2024 and still relies on external collaborations to expand reach.
- Multiple indications
- Broader development scope
- External platform validation
Singapore EDB and Duke-NUS LUNAR-COV19 support
Arcturus Therapeutics Holdings Inc. worked with the Singapore Economic Development Board and Duke-NUS Medical School on LUNAR-COV19, tying its vaccine work to Singapore-based research and infrastructure. The deal helped broaden its infectious-disease network and gave the program local scientific and development support.
- Singapore EDB supported the partnership
- Duke-NUS backed LUNAR-COV19 research
- Strengthened Arcturus’ infectious-disease reach
Arcturus Leans on Key Partners to Expand RNA Reach
Arcturus Therapeutics Holdings Inc. depends on partners to push RNA programs into trials, manufacturing, and local reach. Vinbiocare backs Vietnam COVID-19 scale-up, while Janssen, Ultragenyx Pharmaceutical, Inc., and CureVac AG extend its pipeline across hepatitis B, rare disease, and mRNA work.
| Partner | Role | Key fact |
|---|---|---|
| Vinbiocare | Manufacturing | ARCT-154 55.2% efficacy |
| Janssen | HBV therapy | ~254M HBV cases |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Arcturus Therapeutics Holdings Inc., mapping its mRNA platform, partnerships, and value creation across all 9 blocks.
Customizable Excel Spreadsheet
Quickly clarifies Arcturus Therapeutics’ business model to spot pain points and decision gaps fast.
Reference Sources
Arcturus Therapeutics Holdings Inc. Reference Sources provide a clear, credible trail that helps validate key assumptions and speed better decisions.
Activities
RNA medicine discovery
Arcturus Therapeutics Holdings Inc. builds RNA medicines with its internal platform, starting discovery with target selection and construct design. The work spans two core paths, vaccines and therapeutics, so each program is shaped for the right biology and delivery from the start.
Clinical development of LUNAR programs
Arcturus’s key activity is clinical execution across 4 LUNAR programs: LUNAR-OTC, LUNAR-CF, LUNAR-COV19, and LUNAR-FLU, covering rare liver, respiratory, and infectious diseases. This pipeline is the main value driver, since each trial can expand the company’s RNA medicine platform and move assets toward milestone-based financing and future revenue.
Partnership-led co-development
Arcturus Therapeutics Holdings Inc. uses partnership-led co-development with pharma, biotech, and academic groups to share technical and financial risk across 3 partner types. This model also gives Arcturus faster access to outside know-how and helps push RNA programs into new indications without carrying the full cost alone.
Manufacturing and CMC work
Arcturus Therapeutics Holdings Inc. treats manufacturing and chemistry, manufacturing, and controls (CMC) as core work, because RNA and vaccine candidates need tight process development, scale-up, and release testing. The Vinbiocare relationship shows how manufacturing access can shape pipeline progress, since CMC quality drives both speed and regulatory readiness.
- Process development supports scale-up
- CMC underpins regulatory approval
- Vinbiocare shows manufacturing value
Regulatory and translational execution
Arcturus Therapeutics Holdings Inc. uses regulatory and translational execution to turn preclinical RNA candidates into human studies, with data packages built to support IND-ready filings and dose selection. This step is critical because pipeline progress depends on clear regulatory readiness, and Arcturus reported $283.4 million in cash, cash equivalents, and marketable securities at December 31, 2024, funding this work.
- Builds regulatory data packages
- Advances candidates into human testing
- Supports IND and translational studies
- Depends on strong regulatory readiness
Arcturus Advances 4 RNA Programs With $283.4M Cash Cushion
Arcturus Therapeutics Holdings Inc. focuses on RNA discovery, clinical development, and CMC manufacturing across its lead programs, including LUNAR-OTC, LUNAR-CF, LUNAR-COV19, and LUNAR-FLU. Its key work is moving RNA assets from design to human data while keeping cash discipline; it reported $283.4 million in cash, cash equivalents, and marketable securities at December 31, 2024.
| Key activity | Relevant data |
|---|---|
| Clinical execution | 4 LUNAR programs |
| Liquidity | $283.4 million cash and marketable securities |
| Partnership model | Shared risk in co-development |
Delivered as Displayed
Business Model Canvas
This preview shows the actual Arcturus Therapeutics Holdings Inc. Business Model Canvas document you will receive after purchase. It is not a sample or mockup—it's a live preview of the final file. Once you complete your order, you’ll get the same fully formatted document, ready to download, edit, and use with confidence.
Resources
LUNAR RNA delivery platform
Arcturus Therapeutics Holdings Inc.’s LUNAR RNA delivery platform is its core resource, and it drives both the vaccine and therapeutic pipeline. The platform is central to the company’s edge in RNA medicines because delivery is the key step that turns RNA design into a usable drug.
Pipeline assets in rare disease and vaccines
Arcturus Therapeutics Holdings Inc. has four named pipeline assets in rare disease and vaccines: LUNAR-OTC, LUNAR-CF, LUNAR-COV19, and LUNAR-FLU. That mix gives the Company multiple shots on goal across both therapy and prevention, reducing dependence on any one program while keeping optionality in two large markets.
Strategic collaboration network
Arcturus Therapeutics Holdings Inc.’s strategic collaboration network is a key resource, with 7 named partners, including Janssen, Ultragenyx, CureVac, Vinbiocare, Millennium, Duke-NUS, and Singapore EDB. These ties extend Arcturus beyond its internal team, adding development and manufacturing capacity that supports pipeline scale and global reach.
Headquarters in San Diego, California
Arcturus Therapeutics Holdings Inc. is based in San Diego, California, a biotech hub that supports recruiting scientists, process engineers, and clinical staff. The city’s life-science cluster gives the Company direct access to research labs, universities, and partners that matter for RNA drug development.
San Diego serves as Arcturus Therapeutics Holdings Inc.'s corporate and research base, helping keep key decisions and R&D close together. In 2025, the Company reported $50.2 million in total revenue, so this location supports a lean operating model with high-value talent nearby.
- San Diego biotech talent pool
- Corporate and research operations base
- Close to labs and life-science partners
Scientific and development expertise
Arcturus Therapeutics Holdings Inc. depends on specialized RNA, vaccine, and translational know-how to pick targets, design formulations, and plan trials. In biotech, human capital is a core asset, and this expertise supports the company’s mRNA platform across 3 linked stages: discovery, delivery, and clinical execution.
- RNA and vaccine science
- Formulation and delivery design
- Clinical planning and translation
Arcturus Turns RNA Innovation Into Real Revenue
Arcturus Therapeutics Holdings Inc.'s key resources are its LUNAR RNA delivery platform, its rare-disease and vaccine pipeline, and its specialist RNA talent in San Diego. In 2025, the Company reported $50.2 million in total revenue, which shows these assets are being turned into real product value.
| Resource | Why it matters | 2025 data |
|---|---|---|
| LUNAR platform | Core RNA delivery engine | 1 core platform |
| Pipeline | Growth optionality | 4 named assets |
| Revenue | Proof of monetization | $50.2 million |
Value Propositions
RNA-based medicines for hard-to-treat diseases
Arcturus Therapeutics Holdings Inc. builds RNA medicines for high-unmet-need diseases, with programs in rare liver and respiratory conditions plus infectious-disease prevention. Its lead COVID-19 vaccine, KOSTAIVE, won approval in Japan in 2024, showing the platform can reach real patients, not just the lab.
LUNAR-OTC for ornithine transcarbamylase deficiency
LUNAR-OTC targets ornithine transcarbamylase (OTC) deficiency, a rare X-linked urea cycle disorder that affects about 1 in 14,000 births and can cause life-threatening ammonia spikes. It fits a precision-medicine model by treating a genetically defined patient group with few durable options, where current care still relies on diet and ammonia-scavenger drugs.
LUNAR-CF for cystic fibrosis lung disease
LUNAR-CF is built for cystic fibrosis lung disease driven by specific CFTR mutations, which matter because CF has more than 2,000 known CFTR variants and about 90,000 people live with the disease worldwide. This mutation-focused design supports a precise respiratory therapy strategy, including patients who may not respond to standard CFTR modulators.
Vaccines for infectious diseases
Arcturus Therapeutics Holdings Inc. is using 2 vaccine programs, LUNAR-COV19 and LUNAR-FLU, to move beyond rare disease into prevention. That matters in a market where influenza still causes about 290,000 to 650,000 respiratory deaths a year, so these candidates target real public-health need.
- 2 named vaccine candidates
- Broadens beyond rare disease
- Targets infectious threats
Partnership-enabled development speed
Arcturus Therapeutics Holdings Inc. uses partnerships to add manufacturing, research, and development capacity without building every function in-house. That model can speed up work across multiple programs, since each partner helps move assets through development and scale-up.
- Expands execution capacity
- Shares R&D and manufacturing load
- Speeds multiple programs
Arcturus RNA Therapy Pipeline Targets Rare Diseases and Vaccines
Arcturus Therapeutics Holdings Inc. offers RNA drugs for hard-to-treat diseases, with value built on precise, mutation-linked programs in rare liver and lung disorders plus vaccines. Its platform has reached patients through KOSTAIVE approval in Japan in 2024, while partnerships help spread R&D and manufacturing cost and speed.
| Value proposition | Key data |
|---|---|
| Precision rare-disease RNA | LUNAR-OTC targets 1 in 14,000 births |
| Respiratory precision therapy | LUNAR-CF fits 2,000+ CFTR variants |
| Infectious-disease prevention | 2 vaccine programs: LUNAR-COV19, LUNAR-FLU |
Customer Relationships
Strategic B2B collaboration management
Arcturus Therapeutics Holdings Inc. builds long-term ties with corporate and academic partners through development collaborations, and this is central to its operating model. In fiscal 2025, those partnerships still helped fund mRNA pipeline work and share R&D risk, keeping external collaboration at the core of value creation.
Shared development governance
Arcturus Therapeutics Holdings Inc. runs shared development governance through joint program reviews, milestone checks, and data sharing with partners; this is standard biotech co-development. In 2025, the model still fits a pipeline built on partnered RNA programs, where each decision needs both science and project control.
Clinical-trial participant engagement
Arcturus Therapeutics Holdings Inc. builds clinical-trial participant engagement through clear consent, steady follow-up, and safety communication for its mRNA therapy and vaccine studies. This matters because human data only comes from volunteers, and strong retention and reporting help keep trials on track and improve data quality.
Scientific and regulatory communication
Arcturus Therapeutics Holdings Inc. keeps scientific and regulatory ties active with investigators, regulators, and research institutions to build evidence and support approvals for RNA candidates. In FY2025, this work sat behind its clinical pipeline and helped move data packages through study sites and review channels.
- Supports trial evidence and approval filings
- Links Company Name with regulators and investigators
- Helps advance RNA candidates through review
Investor and stakeholder relations
Arcturus Therapeutics Holdings Inc. keeps investor and stakeholder relations active through program updates, SEC filings, and earnings calls, which matters because public biotech funding depends on trust as much as data. In its latest reported year, the Company held $216.5 million in cash, cash equivalents, and investments, giving it room to keep communicating while funding development.
- Shares pipeline progress and trial milestones
- Publishes required corporate disclosures
- Builds trust to support capital access
Arcturus Builds RNA Progress Through Partner-Led R&D and Shared Risk
Arcturus Therapeutics Holdings Inc. keeps customer relationships anchored in partner-led R&D, with joint governance, milestone reviews, and data sharing that share risk and keep RNA programs moving. In FY2025, this model still depended on corporate and academic collaboration to fund pipeline work and support trial execution.
| Relationship type | FY2025 signal |
|---|---|
| Development partners | Shared R&D risk |
| Trial participants | Consent and follow-up |
| Investors | $216.5m cash and investments |
Channels
Collaborative partner agreements
Arcturus Therapeutics Holdings Inc. reaches customers and partners mainly through licensing and collaboration agreements, which remain the core path for external program development. These contracts set the work scope and commercial rights, and Arcturus has continued to use partner-funded programs to advance its pipeline while reporting collaboration revenue in recent filings.
Clinical trial sites and investigators
Clinical trial sites and investigators are Arcturus Therapeutics Holdings Inc.’s direct channel for enrolling patients and collecting endpoint data across Phase 1-3 studies. In 2025, these hospital and research-center partners were essential to prove safety and efficacy before any broader regulatory step.
Corporate investor communications
Arcturus Therapeutics Holdings Inc. uses SEC filings, earnings materials, and investor updates to keep capital markets and shareholders informed on pipeline progress. In FY2025, this channel mix helps explain clinical and regulatory milestones, while the company’s public reporting remains the main way investors track cash use, trial timing, and program risk.
Scientific conferences and publications
Arcturus uses scientific conferences and peer-reviewed publications to share platform and program data with researchers, partners, and potential collaborators, which helps validate its mRNA and delivery results. These channels matter because they are where technical proof gets checked, debated, and used to build new partnerships.
- Reaches researchers and collaborators
- Supports data validation
- Builds scientific credibility
Partner manufacturing and development networks
Arcturus Therapeutics Holdings Inc. uses partner manufacturing and development networks, including facilities like Vinbiocare, to extend production and development beyond its own sites. That setup supports faster regional execution and helps Arcturus Therapeutics Holdings Inc. scale programs without building every plant itself.
- Expands reach through partner sites
- Supports regional execution
- Helps scale without full buildout
It also lowers single-site dependence, which matters when demand or tech transfer moves faster than internal capacity.
Arcturus Advances mRNA Growth Through Partners, Trials, and Filings
Arcturus Therapeutics Holdings Inc. mainly uses licensing and collaboration deals, clinical trial sites, and public filings to reach partners, patients, and investors. In FY2025, this channel mix supported partner-funded development, trial execution, and capital-markets visibility as the company advanced its mRNA pipeline.
| Channel | FY2025 role |
|---|---|
| Partners | Collaboration revenue |
| Trial sites | Patient enrollment |
| SEC filings | Investor updates |
Customer Segments
Patients with rare liver disease
Patients with rare liver disease here means people with ornithine transcarbamylase (OTC) deficiency, the main target group for Arcturus Therapeutics Holdings Inc.'s LUNAR-OTC. OTC deficiency is the most common urea cycle disorder, with an estimated prevalence of about 1 in 56,500 live births, and these patients need disease-modifying treatment options, not just ammonia control.
Patients with cystic fibrosis lung disease
This segment targets patients with cystic fibrosis caused by specific CFTR mutations, a genetically defined population that LUNAR-CF is built to serve. Cystic fibrosis affects about 105,000 people worldwide, including roughly 40,000 in the U.S., so the commercial focus is on a clear respiratory disease niche with measurable unmet need.
Infectious-disease vaccine markets
Arcturus Therapeutics Holdings Inc. serves the preventive-health infectious-disease vaccine market, targeting people needing COVID-19 and influenza protection through LUNAR-COV19 and LUNAR-FLU. The addressable market is large: WHO says influenza infects about 1 billion people yearly, with 3–5 million severe cases, while COVID-19 remains a recurring vaccination need.
Pharmaceutical and biotech partners
Arcturus Therapeutics Holdings Inc. treats pharmaceutical and biotech partners as a core customer segment: Janssen, Ultragenyx, CureVac, Vinbiocare, and Millennium use its LUNAR platform for co-development and platform access. This partner-led model drives collaboration revenue and de-risks R&D by sharing development costs and milestones.
- Core buyers: pharma and biotech partners
- Need: platform access
- Need: co-development support
- Key names: Janssen, Ultragenyx, CureVac
Research and public-health institutions
Research and public-health institutions are strategic partners for Arcturus Therapeutics Holdings Inc., because groups like Duke-NUS and the Singapore Economic Development Board help convert mRNA science into tested programs and regional adoption. Singapore’s R&D spend has stayed near 2% of GDP, so these ties support translation, clinical depth, and fast collaboration.
- Duke-NUS: clinical and translational research
- Singapore EDB: regional innovation support
- Role: co-development and local scale-up
Arcturus Targets Rare Disease, Vaccines, and Pharma Partnerships
Arcturus Therapeutics Holdings Inc. mainly serves three customer groups: rare-disease patients with OTC deficiency and cystic fibrosis, plus people needing mRNA-based vaccines for COVID-19 and influenza. It also sells platform access and co-development work to pharma and biotech partners like Janssen and Ultragenyx, which helps fund R&D.
| Segment | Key data |
|---|---|
| OTC deficiency | ~1 in 56,500 births |
| Cystic fibrosis | ~105,000 global patients |
| Influenza | ~1B cases yearly |
Cost Structure
Research and discovery spending
Arcturus Therapeutics Holdings Inc. must keep funding RNA platform research and target discovery, and that early-stage science is its biggest biotech cost driver. This spend feeds new candidate generation and, in the latest reported periods, research and development has remained the company’s main operating outlay, well above manufacturing and G&A.
Clinical development costs
Clinical development costs are a major R&D drain for Arcturus Therapeutics Holdings Inc., because human trials for LUNAR-OTC, LUNAR-CF, LUNAR-COV19, and LUNAR-FLU need paid sites, monitoring, data management, and analysis. In FY2025, this spending sat alongside total R&D of one of the company’s largest expense lines, reflecting the high cost of moving multiple mRNA programs through clinical testing.
Manufacturing and CMC expenses
Manufacturing and CMC expenses are a core cost for Arcturus Therapeutics Holdings Inc. because RNA and vaccine programs need formulation, process development, and GMP manufacturing runs, plus partner sites add technical transfer and QA work. CMC scale-up is one of the first places costs rise as programs move from lab batches to clinical supply, so it stays a key driver of R&D spend.
General and administrative overhead
Arcturus Therapeutics Holdings Inc. carries steady general and administrative overhead from being a public company, mainly finance, legal, HR, and compliance staff, plus SEC reporting and audit work. These costs are fixed enough to hit margins even before product revenue scales, so they matter in every valuation of the Company.
- Finance, legal, HR, compliance
- SEC reporting and audit expense
- Fixed cost drag on margins
Partnering and regulatory costs
Partnering and regulatory costs stay high for Arcturus Therapeutics Holdings Inc. because collaboration management, licensing support, and FDA-facing submissions are recurring biotech expenses. The company also must keep external alliances active while advancing approvals, so these costs rise with each partnered program and filing cycle.
- Collaboration management adds steady overhead.
- Licensing support raises legal and deal costs.
- Regulatory submissions are recurring cash costs.
Arcturus FY2025: R&D Led the Burn, G&A Stayed Lean
In FY2025, Arcturus Therapeutics Holdings Inc. kept cost structure centered on R&D, with clinical work, CMC scale-up, and RNA platform research as the main cash burns. G&A stayed the next fixed layer, covering public-company and compliance needs.
| FY2025 cost driver | Amount |
|---|---|
| R&D | largest expense line |
| G&A | fixed overhead |
Revenue Streams
Collaboration revenue from partners
Arcturus Therapeutics Holdings Inc. earns collaboration revenue from partners including Janssen, Ultragenyx, CureVac, Vinbiocare, and Millennium, with payments tied to development work, milestones, and reimbursed R&D costs. This partner income is central to the model and helps fund its RNA medicines pipeline.
Upfront and milestone payments
Arcturus Therapeutics Holdings Inc. uses biotech deals with upfront cash and milestone payments, so revenue rises as partners hit tech and clinical steps. For example, CSL Seqirus committed $200 million upfront in 2020, plus up to $328 million in development, regulatory, and sales milestones, tying income to program progress.
Potential royalties on future sales
Potential royalties on future sales can become a durable biotech revenue stream for Arcturus Therapeutics Holdings Inc. if partnered products reach commercialization, but the cash flow is contingent on late-stage success, launch timing, and partner sales performance.
In practice, this means royalty income is back-end value: it can scale after approval, yet it may stay near zero for years if partnered programs do not reach market.
Government and institutional support
Arcturus Therapeutics Holdings Inc. can tap government and institutional support through ties with the Singapore Economic Development Board and Duke-NUS, which can bring non-dilutive funding, shared lab access, and in-kind development help. That kind of backing lowers early program risk before costly clinical work starts.
Access to institutional funding
In-kind R&D support
De-risks early-stage programs
Manufacturing and development-related receipts
Manufacturing and development-related receipts can add a second income layer for Arcturus Therapeutics Holdings Inc., beyond core collaboration fees. The Vinbiocare tie-up shows how vaccine programs can trigger development-linked payments when manufacturing work advances.
These receipts can be irregular, but they can still support cash flow alongside partner revenue.
- Vinbiocare illustrates manufacturing-linked upside.
- Payments can track program milestones.
- They supplement collaboration income.
Arcturus Revenue: Partnerships Drive Cash, Royalties Are the Upside
Arcturus Therapeutics Holdings Inc. revenue is mainly collaboration-based: partner fees, reimbursed R&D, and milestone cash. CSL Seqirus shows the model clearly, with $200 million upfront and up to $328 million in milestones tied to progress. Royalty income is the upside, but it depends on approval and sales.
| Stream | Latest number |
|---|---|
| CSL Seqirus upfront | $200 million |
| CSL Seqirus milestones | Up to $328 million |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.